Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214 Meeting Abstract
| Authors: | McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; Gurney, H.; Grimm, M. O.; Harrison, M. R.; Hutson, T. E.; Yang, S.; Johansen, J.; Rao, S.; Mekan, S. F.; Rael, M.; Powles, T. |
| Abstract Title: | Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214 |
| Meeting Title: | 2019 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2019 Feb 14-16 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-03-01 |
| Language: | English |
| ACCESSION: | WOS:000489108800565 |
| DOI: | 10.1200/JCO.2019.37.7_suppl.564 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 564 -- Source: Wos |
